ストックスクリーナーアプリを入手
6.25
1.26%
-0.08
プレマーケット:
6.16
-0.09
-1.44%
Minerva Neurosciences Inc (NERV) 最新ニュース
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Minerva Neurosciences: Q1 Earnings Snapshot - marketscreener.com
No approved drug targets these schizophrenia symptoms; Phase 3 starts - Stock Titan
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat
Minerva launched with new outperform at Citizens on schizophrenia candidate - MSN
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69 - MSN
Minerva Neurosciences | 8-K: Current report - Moomoo
[ARS] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Officer liability and pay votes at Minerva Neurosciences (NASDAQ: NERV) 2026 meeting - Stock Titan
NERV (Minerva Neurosciences Inc) posts wider than expected Q4 2025 loss yet shares rise 5.28 percent on bullish investor sentiment.ADR - UBND thành phố Hải Phòng
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) officer James O’Connor files Form 3 - Stock Titan
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com South Africa
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest - MarketBeat
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com - Investing.com Australia
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - Investing.com
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Ideas Watch: Is Minerva Neurosciences Inc stock a hidden gemPortfolio Gains Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - Investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):